



Patient Care + Research + Clinical Trials

**Dr. Tom Elliott MBBS, FRCPC
Medical Director**

400 - 210 W Broadway phone: 604.683.3734
Vancouver, BC fax: 604.628.3821
V5Y 3W2 Canada email: moa@bcdiabetes.ca

Extended Medical Insurance for Ozempic/Wegovy & Mounjaro

2024-Jul-24 Third party insurers sometimes deny BCDiabetes patients coverage for [Ozempic / Wegovy](#) & [Mounjaro](#) for reasons that do not make medical sense. These drugs are game-changing: they safely lower sugar & weight and for individuals with established diabetic kidney disease and heart disease they prolong life.

The objective of diabetes care, including the use of Ozempic, Wegovy and Mounjaro is to lower A1c to < 6.0 and to keep it there. This typically requires BCDiabetes clients to take these drugs indefinitely.

To restrict coverage to clients with A1c >6.9 makes no medical sense. Insurers must also cover clients whose A1cs are < 7.0 and in fact < 6.0 because these are their treatment targets.

I will be happy to discuss these issues with you. Do not hesitate to call or email me.

Tom Elliott
Medical Director, BCDiabetes.ca

Short URL = <https://bit.ly/46ISkPf>